Catalera BioSolutions

About Catalera BioSolutions

Catalera BioSolutions Inc. operates as a developer of biological solutions targeting the plant, home, and public health sectors. The company was established in mid-May 2024 as an independent spin-out from Terramera, a Vancouver-based agricultural technology firm. This transition was facilitated by an initial US$8 million Series A funding round led by S2G Ventures, with additional investment from Farm Credit Canada (FCC) Capital. The company's leadership includes CEO Matthew Dahabieh, who previously served as a senior vice president at Terramera and headed its green chemistry solutions division.

The firm addresses the challenges within the $70 billion synthetic chemistry industry for pest control, which faces issues related to food security risks, environmental damage, and negative health impacts from over-reliance on synthetic chemicals. Catalera provides biological alternatives for pest control to a diverse client base that includes growers, homeowners, and professionals in agriculture and public health. The business model centers on the commercialization of biological products, leveraging a foundation of patented technologies inherited from Terramera to accelerate product development and market entry. Revenue is generated through the sale of its proprietary biopesticide products, with options for private labeling and securing rights to future product breakthroughs.

Catalera’s product portfolio includes a range of biological fungicides, insecticides, and miticides. Key commercial products include RANGO®, a biopesticide for specialty crops like vegetables, berries, and tree nuts; SOCORO®, designed for row crops such as corn, cotton, and soybeans; and Vaporpad® for professional bed bug treatments. The company has also registered TRIFECTO® in Mexico for use on specialty crops. These products are developed using a proprietary toolkit of patented technologies, including the Exosect™ Delivery System and Actigate™ Targeting Tech, which are designed to enhance the efficacy, stability, and delivery of biological active ingredients. The company utilizes advanced facilities, including over 16,000 sq. ft. of laboratories with high-throughput screening and simulated environment chambers, to accelerate research and de-risk product development.